| Anti-apoptotic |
Zhang et al., 2002; Dreixler et al., 2008; Peng et al., 2009; Biermann et al., 2010; Biermann et al., 2011; Schallner et al., 2012; Ulbrich et al., 2015
|
Grimm et al., 2002; Bordone et al., 2012
|
|
Kim et al., 2013 |
| Anti-inflammatory |
Nishiyama et al., 2000; Nonaka et al., 2001; Fernandez et al., 2009a; Fernandez et al., 2009b; Biermann et al., 2010; Biermann et al., 2011; Schallner et al., 2012; Halder et al., 2013; Chrysostomou et al., 2014; Pan et al., 2014; Zhang et al., 2014; Wang et al., 2016
|
Zhu et al., 2010; Albarracin et al., 2011; Albarracin and Valter, 2012
|
Bosco et al., 2012; Howell et al., 2012
|
Fernandez et al., 2011; Fernandez et al., 2012; Salido et al., 2013; Dorfman et al., 2014
|
| Anti-oxidative stress |
Zhu et al., 2007; Peng et al., 2009; Peng et al., 2011; Kong et al., 2012; Pan et al., 2014; Zhang et al., 2014; Ulbrich et al., 2015; Wang et al., 2016
|
|
Inman et al., 2013 |
Salido et al., 2013b |
| Anti-lipid peroxidation |
|
Zhu et al., 2010; Bordone et al., 2012
|
Belforte et al., 2011; Inman et al., 2013
|
|
| Changes in metabolism |
Nishiyama et al., 2000; Berkowitz et al., 2008; Fernandez et al., 2009a; Biermann et al., 2011; Kong et al., 2012
|
Barbe et al., 1988 |
Park et al., 2001 |
Fernandez et al., 2012 |
| Changes in signaling intermediates |
Dreixler et al., 2009; Biermann et al., 2010; Biermann et al., 2011; Schallner et al., 2012; Ulbrich et al., 2015
|
Ueki et al., 2008 |
|
Kim et al., 2013 |
| Increased mitogens |
|
Lawson et al., 2014; Brandli et al., 2016
|
|
Dorfman et al., 2014 |
| Improved tissue perfusion |
Lin and Roth, 1999 |
|
|
|
| Improved vascular integrity |
|
|
|
Fernandez et al., 2011; Salido et al., 2013b; Dorfman et al., 2014
|
| Improved axonal transport |
|
Bosco et al., 2012; Inman et al., 2013
|
|
Fernandez et al., 2012 |
| Epigenetic modifications |
Stowell et al., 2010; Fan et al., 2016
|
|
|
|
